scholarly journals Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation

2020 ◽  
Vol 20 (6) ◽  
pp. 407-414 ◽  
Author(s):  
Liana Nikolaenko ◽  
Saurabh Chhabra ◽  
Noa Biran ◽  
Arnab Chowdhury ◽  
Parameswaran N. Hari ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Graft Versus Host Disease ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma

Blood ◽  
2004 ◽  
Vol 103 (11) ◽  
pp. 4362-4364 ◽  
Author(s):  
Henk M. Lokhorst ◽  
Kalung Wu ◽  
Leo F. Verdonck ◽  
Laurens L. Laterveer ◽  
Niels W. C. J. van de Donk ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Graft Versus Host Disease ◽  
Complete Response ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Insufficient Response ◽  
Relapsed Myeloma ◽  
Donor Lymphocyte Infusions

Abstract The graft-versus-myeloma (GVM) effect of donor lymphocyte infusions (DLIs) is well established. We now report the outcome of DLI in 54 patients with relapsed myeloma following allogeneic transplantation. Twenty-eight patients (52%) responded, 19 patients (35%) with a partial response and 9 patients (17%) with a complete response. Progression-free and overall survival were 19 and 23 months, respectively. We found that acute and chronic graft-versus-host disease (GVHD) observed in 57% and 47% of patients, respectively, following DLI were the strongest predictors for response. This suggests that targets for GVHD and GVM are identical. In a subgroup analysis, deletion of chromosome 13, as determined by double-color fluorescence in situ hybridization (FISH), had no impact on outcome, indicating that these patients are candidates for early allogeneic transplantation followed by DLI, in case of insufficient response. (Blood. 2004;103:4362-4364)

Graft-versus-host disease (GVHD) risk with daratumumab (Dara) therapy post allogeneic transplantation (alloHCT) for multiple myeloma (MM).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 8028-8028
Author(s):  
Liana Nikolaenko ◽  
Saurabh Chhabra ◽  
Parameswaran Hari ◽  
Amrita Y. Krishnan ◽  
Joshua Ryan Richter
Keyword(s):  
Multiple Myeloma ◽  
Graft Versus Host Disease ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation

Haematologica ◽  
2007 ◽  
Vol 92 (9) ◽  
pp. 1295-1296 ◽  
Author(s):  
J. Mateos-Mazon ◽  
J.-A. Perez-Simon ◽  
O. Lopez ◽  
E. Hernandez ◽  
J. Etxebarria ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Graft Versus Host Disease ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation

2003 ◽  
Vol 121 (1) ◽  
pp. 104-108 ◽  
Author(s):  
José A. Pérez-Simón ◽  
Rodrigo Martino ◽  
Adrián Alegre ◽  
José F. Tomás ◽  
Angel De Leon ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Graft Versus Host Disease ◽  
Allogeneic Transplantation ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft
Sign in / Sign up

Export Citation Format

Share Document